ERBB2 and breast carcinoma: We recently described a class of agents termed Disulfide bond Disrupting Agents (DDAs) that are capable of breaking disulfide bonds in solution, and when applied to breast cancer cells downregulate HER family members EGFR, HER2, and HER3 in parallel, and inactivate Akt [33].